Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer | Synapse
July 15, 2025
Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Puntos clave
MAIN FINDING: Anti-b- and t-lymphocyte antibody tifcemalimab combined with toripalimab shows promise in advanced lung cancer.
KEY EVIDENCE: Progression-free survival (PFS) results were analyzed according to hvem and pd-l1 expression levels.
APPROACH: The analysis involved previously treated advanced lung cancer patients receiving combination therapy.
SIGNIFICANCE: Understanding hvem and pd-l1's roles may improve treatment strategies for advanced lung cancer patients.
Resumen
Supplementary Figure 5. The exploratory analysis of PFS according to HVEM and PD-L1 expression.